ProShares UltraPro Short NASDAQ Biotechnology logo

ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) Q1 2025 Earnings

ZBIO·Reported May 15, 2025·Before market open

ProShares UltraPro Short NASDAQ Biotechnology reported Q1 2025 revenue of $10.0M, beat analyst consensus of $1.3M by $8.8M. Diluted EPS came in at $-0.80, beat the $-1.11 consensus by $0.31.

Revenue
$10.0Mbeat by $8.8M
Consensus: $1.3M
Diluted EPS
$-0.80beat by $0.31
Consensus: $-1.11
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001558370-25-007803

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about ProShares UltraPro Short NASDAQ Biotechnology's Q1 2025 earnings report.

ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q1 2025 earnings on May 15, 2025 before market open.

ProShares UltraPro Short NASDAQ Biotechnology reported revenue of $10.0M and diluted EPS of $-0.80 for Q1 2025.

Revenue beat the consensus estimate of $1.3M by $8.8M. EPS beat the consensus estimate of $-1.11 by $0.31.

You can read the 10-Q periodic report (0001558370-25-007803) directly on SEC EDGAR. The filing index links above go to sec.gov.